U.S. Markets open in 4 hrs 51 mins

Cerus Corporation (CERS)

NasdaqGM - NasdaqGM Delayed Price. Currency in USD
Add to watchlist
2.68+0.08 (+3.08%)
At close: 4:00PM EDT
People also watch

Cerus Corporation

2550 Stanwell Drive
Concord, CA 94520
United States

Full Time Employees204

Key Executives

Mr. William M. GreenmanPres, Chief Exec. Officer & Director884.97k31.35k50
Dr. Laurence M. Corash M.D.Co-Founder, Chief Scientific Officer & Corp. Director595.71k36.39k73
Mr. Kevin D. GreenVP - Fin. & CFO476.93k15.48k45
Dr. Richard J. Benjamin MBChB, Ph.D.Chief Medical Officer523.13kN/A57
Mr. Vivek K. JayaramanChief Commercial Officer191.06kN/A42
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Cerus Corporation, a biomedical products company, focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System is based on its proprietary technology for controlling biological replication; and targets and inactivates blood-borne pathogens, such as viruses, bacteria, and parasites, as well as harmful white blood cells, while preserving the therapeutic properties of platelet, plasma, and red blood cell transfusion products. The company’s INTERCEPT Blood Systems for platelets and plasma are designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; and INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion. It markets platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. The company was founded in 1991 and is headquartered in Concord, California.

Corporate Governance

Cerus Corporation’s ISS Governance QualityScore as of September 1, 2017 is 9. The pillar scores are Audit: 2; Board: 6; Shareholder Rights: 10; Compensation: 6.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.